Search results for "tumor progression"

showing 10 items of 213 documents

Cathepsin D, B and L circulating levels as prognostic markers of malignant progression

1996

Growing evidence indicates that lysosomal Cathepsins D (CD), B (CB) and L (CL) may promote carcinogenesis and tumor progression. Therefore, we evaluated their potential value as biochemical parameters of malignant progression in patients with benign diseases which may undergo malignant transformation, such as liver cirrhosis (LC) and chronic pancreatitis (CHP) as well as in hepatocellular carcinoma (HCC) and pancreatic cancer (DPC). CD, CB and CL serum levels were determined by immunoenzymatic assays in LC, CHP, HCC or DPC patients and correlated with a number of biochemical and clinical parameters of these diseases. CD serum levels were increased in LC, CHP and HCC, but not in the DPC grou…

AdultAged 80 and overMaleTumor progression.Carcinoma HepatocellularCirrhosiVHepatocellular carcinomaCathepsin LLiver NeoplasmsPancreatic cancerMiddle AgedPrognosisCathepsin DCathepsinsLCathepsin BPancreatic NeoplasmsCysteine EndopeptidasesChronic HepatiticEndopeptidasesBiomarkers TumorHumansFemaleAged
researchProduct

Aging, longevity, inflammation, and cancer.

2005

Cancer rates increase sharply with age in both sexes, and the majority of cases of cancer occur in patients over the age of 65 years. However, the incidence and mortality for cancer level off around 85-90 years of age, followed by a plateau, or even a decline in the last decades of life. Therefore, it seems reasonable to conclude that centenarians are endowed with a peculiar resistance to cancer. Tumor progression is a complex process that depends on interactions between tumor and host cells. One aspect of the host response, the inflammatory response, is of particular interest because it includes the release of proinflammatory cytokines, some of which may promote tumor growth and hence infl…

AdultAgingTime FactorsGenotypemedia_common.quotation_subjectInflammationDiseaseBiologyGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokineImmune systemHistory and Philosophy of ScienceNeoplasmsmedicineHumansRNA MessengerAntigensInterleukin 6media_commonAgedAged 80 and overInflammationInterleukin-6General NeuroscienceLongevityCancerMiddle Agedmedicine.diseaseInterleukin-10Protein Structure TertiaryTumor progressionImmunologybiology.proteinCytokinesmedicine.symptomAnnals of the New York Academy of Sciences
researchProduct

Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implicati…

1997

The serum levels of lysosomal cathepsin B and L and Stefin A, an intracellular inhibitor of these proteolytic enzymes, were determined in patients with hepatocellular carcinoma (HCC) and/or liver cirrhosis (LC) and correlated with some clinical and biochemical parameters of these diseases. Cathepsin B serum levels were increased in HCC and in LC patients as compared to normal subjects (p < 0.001). However no difference was observed between HCC and LC groups. Interestingly, a significant relationship was evidenced between cathepsin B serum content and the grade of severity of cirrhosis (r = 0.41; p < 0.001). Cathepsin L was significantly elevated only in sera of cancer patients as comp…

AdultLiver CirrhosisMaleCancer Researchmedicine.medical_specialtyPathologyCirrhosisCarcinoma HepatocellularHepatocellular carcinomaoteinase inhibitorCathepsin LLysosomal proteinaseGastroenterologyCathepsin BLiver cirrhosiCathepsin BCathepsin LInternal medicineEndopeptidasesmedicineCarcinomaHumansCystatin AStefin AAgedTumor progression.Aged 80 and overEnzyme PrecursorsbiologyLiver NeoplasmsProteolytic enzymesCancerGeneral MedicineMiddle Agedmedicine.diseaseCathepsinsCystatinsPrCysteine EndopeptidasesOncologyCystatin AHepatocellular carcinomabiology.proteinFemalealpha-FetoproteinsLysosomesOncology
researchProduct

Identification of Differentially Expressed Genes in Papillary Thyroid Carcinomas With and Without Rearrangements of the Tyrosine Kinase Receptors RET…

2005

Background The transforming capacities of RET and/or NTRK1 chimeric oncogenes as well as the molecular background of non-rearranged papillary thyroid carcinomas (PTCs) remain to be elucidated. To assess altered gene expression, we examined PTCs with and without tyrosine kinase receptor rearrangements by mRNA differential display (DD). Materials and methods Six of 13 PTCs examined harbored RET chimeras (3× RET/PTC1, 1× RET/PTC3) and/or NTRK1 chimeras (2× trk, 1× TRK-T3, 2 unknown TRK hybrids). The method of DD analysis was refined by a novel fragment-recovery technique using a high-performance fluorescence scanner. Results Of 500 up- or down-regulated mRNA transcripts, 19 selected fragments …

AdultMaleAdolescentendocrine system diseasesDown-RegulationBiologyReceptor tyrosine kinaseGene expressionHumansThyroid NeoplasmsReceptor trkAGeneAgedCell ProliferationGene RearrangementRegulation of gene expressionGene Expression ProfilingProto-Oncogene Proteins c-retGene rearrangementMiddle AgedCarcinoma PapillaryUp-RegulationGene Expression Regulation NeoplasticGene expression profilingTumor progressionTrk receptorDisease ProgressionCancer researchbiology.proteinFemaleSurgeryJournal of Surgical Research
researchProduct

Predictive chromosomal clusters of synchronous and metachronous brain metastases in clear cell renal cell carcinoma

2014

Synchronous (early) and metachronous (late) brain metastasis (BM) events of sporadic clear cell renal cell carcinoma (ccRCC) (n = 148) were retrospectively analyzed using comparative genomic hybridization (CGH). Using oncogenetic tree models and cluster analyses, chromosomal imbalances related to recurrence-free survival until BM (RFS-BM) were analyzed. Losses at 9p and 9q appeared to be hallmarks of metachronous BM events, whereas an absence of detectable chromosomal changes at 3p was often associated with synchronous BM events. Correspondingly, k-means clustering showed that cluster 1 cases generally exhibited low copy number chromosomal changes that did not involve 3p. Cluster 2 cases ha…

AdultMaleCancer ResearchDNA Copy Number VariationsMedizinChromosome 9BiologySporadic Clear Cell Renal Cell Carcinoma03 medical and health sciences0302 clinical medicineGeneticsmedicineHumansCarcinoma Renal CellMolecular BiologyAgedRetrospective StudiesSequence Deletion030304 developmental biologyAged 80 and overChromosome AberrationsGeneticsComparative Genomic Hybridization0303 health sciencesBase SequenceBrain NeoplasmsChromosomeDNA NeoplasmMiddle Agedmedicine.diseaseKidney NeoplasmsClear cell renal cell carcinomaTumor progression030220 oncology & carcinogenesisCancer researchFemaleNeoplasm Recurrence LocalLow copy numberComparative genomic hybridizationBrain metastasisCancer Genetics
researchProduct

Expression of nm23 in gastric carcinoma: association with tumor progression and poor prognosis.

1998

BACKGROUND Expression of nm23 has been shown to be inversely correlated with the metastatic potential of several human cancers. In the current study, the expression and prognostic impact of nm23 was immunohistochemically studied in 413 curatively resected gastric carcinomas. METHODS Tumor sections of the 413 gastric carcinomas were stained with a polyclonal antibody that was raised against the nm23-H1/NDP kinase A, which is identical to the nm23-H1 gene product. RESULTS Expression of nm23 was detected in 84.5% (n = 349) of all tumors, in the majority of cases (71.2%) causing a homogeneous staining reaction in more than 75% of tumor cells. Expression of nm23 was positively correlated with th…

AdultMaleCancer ResearchMetastasisAntigens NeoplasmStomach NeoplasmsLymphatic vesselBiomarkers TumorMedicineHumansLymph nodeAgedMonomeric GTP-Binding ProteinsAged 80 and overbusiness.industryStomachCarcinomaCancerMiddle AgedNM23 Nucleoside Diphosphate Kinasesmedicine.diseasePrognosisSurvival Analysismedicine.anatomical_structureOncologyTumor progressionNucleoside-Diphosphate KinaseCancer researchAdenocarcinomaImmunohistochemistryFemalebusinessCarcinoma Signet Ring CellTranscription FactorsCancer
researchProduct

Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular…

2013

Cholangiocellular carcinoma (CCA) is a primary hepatic malignancy derived from cholangiocytes. The prognosis for CCA patients is very poor and conventional chemotherapy has been proven ineffective in improving long‑term patient survival rates. Organic cation transporters (OCTs) mediate the transport of a broad spectrum of endogenous substrates and the detoxification of xenobiotics. Moreover, OCTs are considered responsible for the responsiveness towards platinum‑based chemotherapies. Currently, there are no data available regarding the role of OCTs in CCA. Therefore, the aim of this study was to investigate the expression of OCT1 and OCT3 in CCA and the corresponding non-neoplastic tumor‑su…

AdultMaleCancer ResearchOrganic Cation Transport ProteinsDown-RegulationKaplan-Meier EstimateBiologySLC22A3CholangiocarcinomaDownregulation and upregulationWestern blotmedicineHumansRNA MessengerAgedAged 80 and overOncogenemedicine.diagnostic_testOrganic Cation Transporter 1CancerMiddle Agedmedicine.diseaseMolecular medicineBile Ducts IntrahepaticBile Duct NeoplasmsOncologyTumor progressionDisease ProgressionCancer researchbiology.proteinImmunohistochemistryFemaleNeoplasm Recurrence LocalInternational Journal of Oncology
researchProduct

Elevated serum E-selectin in patients with liver metastases of colorectal cancer

1996

E-selectin, an endothelial cell adhesion molecule, mediates the initial step of leucocyte adhesion to activated vascular endothelium. The soluble isoform of E-selectin promotes angiogenesis in rat cornea. In the present study, we investigated whether leucocyte adhesion and angiogenesis are also involved in tumour progression and metastasis of colorectal cancer. Therefore, we determined the level of circulating soluble E-selectin in serum samples of 38 patients with colorectal cancer; 20 patients with non-metastatic and 18 patients with metastatic disease. Median levels of soluble E-selectin were found to be significantly higher in metastatic tumour disease (88.7 ng/ml, range 25-203 ng/ml) t…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyAngiogenesisColorectal cancerFibrinogenMetastasisE-selectinmedicineCarcinomaHumansAgedbiologyTumor Necrosis Factor-alphaCell adhesion moleculebusiness.industryLiver NeoplasmsMiddle Agedmedicine.diseaseNeoplasm ProteinsC-Reactive ProteinSolubilityOncologyTumor progressionCancer researchbiology.proteinFemaleColorectal NeoplasmsE-Selectinbusinessmedicine.drugEuropean Journal of Cancer
researchProduct

Association of loss of 1p and alterations of chromosome 14 in meningioma progression

2004

Meningiomas are usually benign tumors; however, they can recur after surgical resection and occasionally show histologic progression to a higher grade II and III malignancy. The second most frequently reported genetic abnormality after 22q loss is deletion of 1p, although alterations in 9q, 10q, and 14q are also implicated in meningioma progression. Fourteen tumors comprising six benign, four atypical, and four malignant meningiomas were examined by means of cytogenetic and fluorescence in situ hybridization analysis. All tumors showed losses in different regions of 1p, with 1p11, 1p13, 1p21, 1p22, 1p32, and 1q21 breakpoints; eight tumors also presented alterations of chromosome 14. Five of…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyBiologyBioinformaticsMalignancyMeningiomaMonosomyGeneticsmedicine1p DeletionHumansMolecular BiologyIn Situ Hybridization FluorescenceAgedChromosomes Human Pair 14medicine.diagnostic_testBreakpointChromosomeMiddle Agedmedicine.diseaseHistologic ProgressionChromosomes Human Pair 1Tumor progressionKaryotypingFemaleChromosome DeletionMeningiomaFluorescence in situ hybridizationCancer Genetics and Cytogenetics
researchProduct

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1997

Peptides derived from melanocyte differentiation antigens have been identified as targets for MHC class I-restricted cytolytic T lymphocytes (CTLs) in human melanoma Regression of antigen-expressing tumors as well as selection of antigen-loss variants in the presence of antigen-specific CTLs have previously been reported. In the present study, we determined the expression of the melanocyte differentiation antigens Melan A/MART-1 and tyrosinase by mRNA analysis and by immunohistochemical staining with the monoclonal antibodies (MAbs) A103 and T311. Co-expression of Melan A/MART-1 and tyrosinase was detected by both methods in 18/20 melanomas tested. However, immunohistochemistry provided add…

AdultMaleCancer ResearchSkin Neoplasmsmedicine.drug_classBiopsyGenes MHC Class I10050 Institute of Pharmacology and Toxicology610 Medicine & healthMonoclonal antibodyPolymerase Chain ReactionMART-1 AntigenMelanocyte differentiationAntigenAntigens NeoplasmMHC class IHLA-A2 AntigenmedicineHumans1306 Cancer ResearchRNA MessengerMelanomaAgedDNA PrimersAged 80 and overbiologyMonophenol MonooxygenaseLiver NeoplasmsMiddle AgedImmunohistochemistryNeoplasm ProteinsCytolysisCTL*OncologyTumor progressionLymphatic MetastasisImmunologyCancer researchbiology.proteinImmunohistochemistry570 Life sciences; biologyFemale2730 Oncology
researchProduct